LA SCELTA DEL MIGLIOR SITO DI STIMOLAZIONE VENTRICOLARE SINISTRA: QUALI NUOVI STRUMENTI ABBIAMO A DISPOSIZIONE?


**Giulio Zucchelli** 

U.O. Malattie Cardiovascolari II Azienda Ospedaliero Universitaria Pisana

Pisa


Advance in cardiac arrhythmias and great innovations in cardiology Torino , 25-27 Ottobre 2012







### **CRT** Nonresponders: Causes



### **CRT** Nonresponders: Causes

#### No Dyssynchrnony

#### **Subopt Leads Position**





LV Scar Burden

Subopt Programming

### CRT "Optimal" Lead Position

Selecting the "right" patient for CRT but stimulating the "wrong" site remains an important cause of nonresponsiveness.

# Probably the notion that with CRT "one size-fits-all strategy" does not work.





#### **"Optimal" Lead Position**

The optimal lead position may theoretically be defined by the positioning of the pacing lead that

maximizes the haemodynamic benefits of CRT (?)

provides superior long-term outcome (!)





#### Role of RV & LV Leads

- RV and LV pacing leads generate 2 ventricular activation wavefronts, which move in opposite directions towards each other.
- The benefit of CRT lies in effective fusion of wavefronts, synchronizing the walls of the LV.
- Optimal" position may be identified for both RV and LV Leads?



### **CRT** LV pacing sites

### Transvenous Endocardial LV pacing Vs

## Transvenous Epicardial LV pacing



### **Endocardial LV pacing??**

- 1. Less transmural dispersion of repolarization
- 2. Less dependent on the timing and position of LV pacing (broader activation wavefronts)
- 3. LV endocardial sites are more centrally located than epicardial sites
- Subendocardial non Purkinje fibers conduct impulses faster, especially in a longitudinal direction





### 2. LV Lead Positions


LV activation pattern is often unpredictable

LBBB is associated with a U-shaped activation pattern that travels via the apex, with the lateral and posterolateral portions of the left ventricle being activated last

This spread of electrical activity correlates well with mechanical activation and has been the main determinant of the conventional implantation approach of positioning the LV leads in a lateral location.



### **CRT** 2. LV Lead Positions





Department of Cardiovascular Diseases 2 - University Hospital of Pisa

Regoli, Auricchio, Europace 2009



#### 2. LV Lead Positions

A high level of heterogeneity in the depolarization wave front of the LV and a wide variance in the area of latest LV activation.

The presence of a scar may shift the region of latest activation

Even in the nonischemic heart, LV activation can be influenced by the spatial conductive properties of the substrate



### 2. LV Lead Position: Strategy

Radiological/Anatomical
Mechanical
Electrophysiological



### 2. LV Lead Position: Strategy

### Radiological/Anatomical





#### 2. LV Lead: R/A Strategy

Fluoroscopy is the principal imaging modalitity used by CRT implanters in clinical practice.

In acute studies, the lateral LV free wall appears to be the optimal pacing site in terms of the rate of rise of LV pressure (dP/dt).\*

Clinical studies, however, have failed to show a consistent effect of LV lead position on symptomatic response or mortality. \*\*



Department of Cardiovascular Diseases 2 - University Hospital of Pisa


\* Butter et al, Circulation 2001

- \*\* Gasparini et al, PACE 2003
- \*\* Kronborg et al, Europace 2009

#### **CRT** 2. LV Lead Position: CRT Trials

Trial	RV Lead Position	LV Position
MUSTIC 2001	<i>"RV lead was positioned <mark>as far as possible from the LV</mark> lead."</i>	"The target site was preferably the lateral wall, midway between base and apex, but other lateral or posterior sites were also acceptable. The great cardiac vein or the middle cardiac vein was used only when other sites were not accessible."
MIRACLE 2002	"a standard right ventricular lead."	"LV lead which was placed into a <mark>distal cardiac vein</mark> "
COMPANION 2004	"use of commercially available leads for RV pacing or for pacing with defibrillation."	"A distal branch of the coronary sinus vein chosen by the physician for LV stimulation. Correct placement of the coronary venous or left ventricular lead was subsequently verified radiographically"
CARE HIF 2005	"the use of standard RV lead."	<i>"Investigators were asked to position the LV lead to pace the lateral or posterolateral left ventricular wall transvenously and provide radiographic documentation."</i>
MADIT CRT 2009	<b>"Standard techniques</b> were used to implant the CRT– ICD."	"Standard techniques were used to implant the CRT–ICD"

#### **CRT** LV Lead Position: Guidelines 2007



Preference for the implantation site is usually given to the lateral and the postero-lateral regions of the LV,<sup>373</sup> corresponding to regions B–D of the proposed schema (*Figure B.1*). Even more important is placing the LV lead in a basal or median section of these three regions, avoiding the apical section, which is too close to the right ventricular lead.

( Guidelines for cardiac pacing and cardiac resynchronization therapy

The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association

#### LV Lead Position: Guidelines 2010-2012

#### 2010 Focused Update of ESC guidelines on device therapy in heart failure

An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy

### NO INDICATIONS ON LEAD POSITION

#### ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012


The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

#### LV Lead Position: Consensus CRT 2012

The final position of the LV pacing lead depends on the <u>anatomy of the cardiac venous system</u>, the performance and stability of the pacing lead, and the absence of PNS.




#### LV Lead Position: No vessel



Zucchelli G. In: Transvenous lead extraction. Bongiorni ed. Springer 2011

#### LV Lead Position: Branch stenosis



Zucchelli G. In: Transvenous lead extraction. Bongiorni ed. Springer 2011



#### LV Lead Position: CS subocclusion




Zucchelli G. In: Transvenous lead extraction. Bongiorni ed. Springer 2011

CRT

#### LV Lead Position: Consensus CRT 2012

Recent reports, including those from the MADIT-CRT\* and REVERSE-HF<sup>+</sup> study, have shown that an apically positioned LV lead location is associated with a worse clinical outcome.




\*Singh et al. Circulation 2011 † Thebault C et al. Eur Heart J 2012

CRT


#### LV Lead Position: Consensus CRT 2012


The COMPANION and MADIT-CRT studies recently showed a <u>comparable response</u> between lateral, anterior, or posterior LV lead locations.

Recent data from the **REVERSE-HF** maintain the <u>potential benefit of a lateral lead location</u>.



### **CRT** 2. LV Lead Position: optimal position??







Department of Cardiovascular Diseases 2 - University Hospital of Pisa

Europace (2009) 11, 1177–1182 doi:10.1093/europace/eup202

CLINICAL RESEARCH Pacing and CRI


#### Long-term clinical outcome and left ventricular lead position in cardiac resynchronization therapy


Mads Brix Kronborg<sup>1</sup>\*, Andi Eie Albertsen<sup>2</sup>, Jens Cosedis Nielsen<sup>1</sup>, and Peter Thomas Mortensen<sup>1</sup>

### CRT 2. LV Lead: R/A Strategy

#### **Circumferential**

#### Longitudinal








Foley et al, PACE 2011

#### **CRT** 2. LV Lead: R/A Strategy


#### **Circumferential**

#### Longitudinal



#### Foley et al, PACE 2011

#### **CRT** 2. LV Lead: R/A Strategy





#### Foley et al, PACE 2011

### 2. LV Lead Position: Strategy

# Radiological/Anatomical Mechanical



### 2. LV Lead Position: Mech Strategy

Mechanical strategy is based on the identification of the latest (viable) mechanical LV contraction and on the lead/segment concordance.



### 2. LV Lead Position: Mech Strategy

Echocardiography
 TDI (PW, Colour, Colour 3D)
 TDI Derived Strain
 2D Derived Strain
 TSI
 TT

Real Time 3D

# Nuclear Imaging SPECT

- CT
- MRI




Location Timing



Substrate

Ypenburg et al, Non invasive imaging in CRT, PACE 2008

### 2. LV Lead Position: Mech Strategy








Department of Cardiovascular Diseases 2 - University Hospital of Pisa

Ansalone et al, JACC 2002

#### 2. LV Lead Position: Mech Strategy









#### Ypenburg et al, JACC 2008

#### 2. LV Lead Position: Mech Strategy






Department of Cardiovascular Diseases 2 - University Hospital of Pisa




#### Ypenburg et al, JACC 2008

#### 2. LV Lead Position: Mech Strategy

Model		Harrell C-Concordance Statistic Index
1	Clinical parameters	0.659
2	Clinical parameters+LV dyssynchrony	0.703
3	Clinical parameters+LV dyssynchrony+ discordant LV lead position	0.732
4	Clinical parameters+LV dyssynchrony+ discordant LV lead position+Myocardial scar	0.751



Larger baseline LV dyssynchrony predicted <u>superior long-term survival</u>, whereas discordant LV lead position and myocardial scar predicted <u>worse</u> <u>outcome</u>.





#### Delgado et al, Circulation 2011

### 2. LV Lead Position: Strategy

Radiological/Anatomical
Mechanical
Electrophysiological



### 2. LV Lead Position: EP Strategy

Since CRT is a form of electrical therapy for disorderly electrical activation of the heart, it makes sense to attempt to target the region with the maximal electrical delay.



## 2. LV Lead Position: EP Strategy

Singh et al. reported that LV delay:


- correlates directly with acute haemodynamic response LV dP/dtmax.
- the percentage of LV delay as a function of QRS duration predicted also chronic clinical outcomes after 1 y.
- Data recently confirmed by a randomized multicenter trial.



#### 2. LV Lead Position: EP Strategy

A practical strategy is the intra-procedural use of intracardiac electrograms to measure the LV lead electrical delay (LVLED) to help individualize lead placement.

This delay is corrected for the baseline QRS (recorded simultaneously) by expressing it as a percentage of the baseline QRS duration.





Department of Cardiovascular Diseases 2 - University Hospital of Pisa

#### Gold et al, EHJ 2011

### 2. LV Lead Position: EP Strategy

Table 3 The left ventricular end-systolic volume and QOL response rates for the QLV quartiles

QLV	n	LVESV r rate (%)	esponse	QOL respons rate (%)	e
0–70 ms	124	38.7		50.0	
70–95 ms	98	39.8		54.6	
95–120 ms	109	57.8		65.1	
120–195 ms	95	68.4		72.0	
Pearson $\chi^2$		< 0.001		0.004	


Table 4	Multivariate logistic regression model
results <sup>a</sup>	

Covariate	Odds ratio (95% CI), P-value				
	LVESV response	QOL response			
QLV 2nd quartile vs. 1st quartile	1.10 (0.62–1.95), 0.743	1.30 (0.75–2.26), 0.355			
QLV 3rd quartile vs. 1st quartile	1.86 (1.04–3.31), 0.036	1.86 (1.05–3.31), 0.033			
QLV 4th quartile vs. 1st quartile	3.21 (1.58–6.50), 0.001	2.73 (1.35–5.54), 0.005			
Age (per 1 year increase)	1.00 (0.98–1.02), 0.801	0.99 (0.97–1.01), 0.209			
LVEF (per 1% increase)	0.98 (0.94–1.01), 0.186	1.00 (0.96–1.03), 0.83			
lschaemic vs. non-ischaemic	0.58 (0.37–0.91), 0.019	1.05 (0.67–1.64), 0.846			
QRS (>150 ms vs. ≤150 ms)	0.86 (0.53–1.40), 0.543	0.88 (0.55–1.43), 0.611			
LBBB vs. non-LBBB	1.20 (0.72-2.01), 0.48	1.17 (0.71–1.93), 0.526			
Male vs. Female	0.53 (0.33-0.85), 0.008	0.56 (0.34-0.91), 0.018			
NYHA class IV vs. I—III	1.67 (0.44–6.29), 0.45	3.41 (0.69–16.92), 0.133			
LVESV	1.00 (0.99-1.01), 0.98	1.00 (0.99–1.00), 0.682			

#### Gold et al, EHJ 2011



#### 2. LV Lead Position: EP Strategy





Gold et al, EHJ 2011

Department of Cardiovascular Diseases 2 - University Hospital of Pisa

#### QRS(BVp)/QRS(RVp)

Electrocardiographic and electrophysiological parameters (acronyms)

Right ventricular pacing (RVp)

S(RVp)-LVegm, ms

QRS(RVp), ms

S(RVp)-LVegmi

Left ventricular pacing (LVp)

S(LVp)-RVegm, ms

QRS(LVp), ms S(LVp)-RVegm<sub>i</sub>

Biventricular pacing (BVp)

QRS(BVp), ms

QRS(BVp)/QRS(basal)

ORS(BVp)/ORS(RVp)

QRS(BVp)/QRS(LVp)

QRS(BVp)/QRS(RVp-LVp)mean

The interval between the onset of the RVp and the onset of the LV lead electrogram QRS duration during RVp

The ratio of S(RVp)-LVegm with QRS(RVp)

The interval between the onset of the LVp and the onset of the RV lead electrogram

QRS duration during LVp

The ratio of S(LVp)-RVegm with QRS(LVp)

QRS duration during BVp

The ratio of QRS(BVp) with QRS(basal)


#### The ratio of ORS(BVp) with ORS(RVp)

The ratio of QRS(BVp) with QRS(LVp)

The ratio of QRS(BVp) with QRS mean duration during LVp and RVp

RV indicates right ventricular, LV left ventricular, RVp indicates right ventricular pacing, LVp left ventricular pacing, BVp indicates biventricular pacing.

#### QRS(BVp)/QRS(RVp) = 0.71





### 2. LV Lead Position: EP Strategy


Table 3 Electrocardiographic parameters of responders and non-responders group

	Responders (n = 45)	Non-responders (n = 34)
QRS(RVp), ms	209.9 ± 22.3	209.4 ± 23.5
QRS(LVp), ms	215.7 ± 30	214.6 ± 31.4
QRS(BVp), ms	154.2 ± 16.9*	167.6 ± 26.6
QRS(BVp)/QRS(RVp)	$0.74 \pm 0.05^{\dagger}$	0.8 ± 0.1
QRS(BVp)/QRS(LVp)	0.72 ± 0.08*	0.79 ± 0.13
QRS(BVp)/QRS(RVp-LVp)mean	$0.73 \pm 0.05^{\$}$	0.79 ± 0.1
QRS(BVp)/QRS(basal)	0.95 ± 0.17	$1.02 \pm 0.2$

See Methods for the acronyms.


\*P < 0.05,  $^{\dagger}P < 0.005$ ,  $^{\$}P < 0.01$  for responders vs. non-responders.

### 2. LV Lead Position: EP Strategy



The value with the optimal predictive accuracy was 0.78. with positive and negative predictive of 70% and 76% respectively.


#### 2. LV Lead Position: EP Strategy






Role of intraoperative electrical parameters in predicting reverse remodelling after cardiac resynchronization therapy and correlation with interventricular mechanical dyssynchrony

Giulio Zucchelli<sup>1+</sup>, Ezio Soldati<sup>1</sup>, Andrea Di Cori<sup>1</sup>, Raffaele De Lucia<sup>1</sup>, Luca Segreti<sup>1</sup>, Gianluca Solarino<sup>1</sup>, Gabriele Borelli<sup>2</sup>, Vitantonio Di Bello<sup>1</sup>, and Maria Grazia Bongiorni<sup>1</sup>





Correlation between RVegm-LVegm and IVMD/delta IVMD

# **CRT RV/LV Lead Position**

Radiological/Anatomical
Mechanical
Electrophysiological




LVL

RVL




Department of Cardiovascular Diseases 2 - University Hospital of Pisa

# New technology










All patient and clinic data displayed are fictitious and for demonstration purposes only.



1. Take two venograms



2. Trace coronary vasculature







All patient and clinic data displayed are fictitious and for demonstration purposes only.




3D Model



Meditronic All patient and clinic data displayed are fict for demonstration purposes only.




Components







All patient and clinic data displayed are fictitious and for demonstration purposes only.









#### 1. CardioGuide 3D

- Create a three-dimensional model of the coronary vasculature.
- Show how Medtronic LV leads match patients anatomy.
- Support LV lead navigation to the target site.

### 2. CardioGuide *m*-Map (future release)

- Identify areas of late mechanical activation.
- Provide recommendations for LV leads and delivery tools

### 3. CardioGuide e-Map (future release)

 Identify areas of late electrical activation and non-viable tissue



All patient and clinic data displayed are fictitious and for demonstration purposes only.





### SonR @ impianto per ottimizzare impianto LV lead

**Obiettivo:** 


Utilizzando il catetere atriale SonR (<u>senza cioè dover</u> <u>aggiungere strumenti invasivi</u>), identificare la miglior configurazione di pacing (fra le diverse disponibili) su <u>base emodinamica</u> (stima LVdP/dt)

Razionale:

SonR è un marker di tipo emodinamico (correla con LVdP/dt)
↓ ritardi EM, ↑ contratt., ↑ DFT ottimizzano
la perform. emodin.


Stato dell'arte: Fase di studi clinici pilota

Courtesy from Sorin



# il sistema SonRmap in sala impianto

Interfaccia Utente SonR-Map su Programm. Orchestra+



# Conclusions

- Pacing the "right" segments in the "right" patient is desirable.
- A purely anatomic approach may be of limited value.
- New technology (Cardio-Guide) could integrate all strategies (radiological, mechanical and EP), and improve results without wasting time.